GPT Healthcare
Current Price
52W ₹115 – ₹175
Quarter Verdict
Q1 FY27Management highlighted strong EBITDA and PAT growth, new clinical capabilities across multiple hospitals, and reiterated the Raipur breakeven timeline with confidence. The PPT language is assertive on occupancy targets, ARPOB trajectory, and the 1,000-bed expansion plan without acknowledging execution risks.
Revenue grew ~18% YoY, driven by a combination of volume and mix improvement across mature hospitals.
Mature hospitals contributed the dominant share of revenue while Raipur remained a small but growing contributor.
Growth quality is high — it is mix-led, with ARPOB rising ~9% YoY as complex procedures increased their share.
Agartala delivered the strongest ARPOB improvement among mature hospitals, up ~17% YoY.
Dum Dum was the highest-revenue hospital in the network, supported by strong occupancy.
EBITDA margin expanded ~300 bps YoY to 20.4%, a meaningful recovery from the prior-year trough.
The improvement was driven by operating leverage on a fixed cost base as mature hospital revenues scaled.
Other Expenses — the largest cost line — declined as a proportion of revenue, indicating better cost absorption.
Employee costs and material costs both grew broadly in line with revenue, suggesting no structural cost pressure.
The margin improvement appears structural for mature hospitals, though Raipur's losses continue to dilute network-level margins.
PAT margin expanded ~280 bps YoY to 9.9%, with PAT surging ~66% YoY — significantly outpacing revenue growth due to operating leverage and a lower effective tax rate from deferred tax credits.
Howrah launched MAKO robotic knee replacement surgeries this quarter, a new high-acuity capability expected to lift ARPOB and reduce average length of stay at that unit.
Agartala completed its comprehensive cancer care platform with PET Scan and Linear Accelerator facilities, making it the only integrated oncology unit in Tripura.
Raipur received a liver transplant licence and commenced its renal transplant programme, marking a meaningful step-up in clinical complexity at the newest hospital.
The specialty revenue mix shifted notably — oncology rose to 1% of network revenue in Q1 FY27 from near-zero in prior periods, while internal medicine and nephrology maintained their dominant shares.
Loading...
| Category | Risk | Commentary |
|---|---|---|
| Operational | Raipur breakeven delay risk | Raipur occupancy stood at 17.4% in Q1 FY27, well below the level required for operational breakeven, with management targeting breakeven by Q3 FY27. If occupancy does not accelerate materially in Q2 FY27, the breakeven timeline will slip and network-level margins will remain under pressure. |
| Operational | Network occupancy far below target | Overall network occupancy was 45.5% in Q1 FY27, significantly below the stated target of 70%, with Raipur dragging the network average down. Even excluding Raipur, mature hospital occupancy at 58% remains well short of the 70% target, indicating the occupancy gap is not solely a Raipur problem. |
| Financial | ROCE declining versus long-term target | Annual ROCE declined from 28.1% in FY24 to 16.5% in FY26, moving further away from the stated long-term target of approximately 25%. The Raipur capital deployment and expansion capex are diluting returns on capital at a time when occupancy across the network remains below optimal levels. |
| Operational | Jamshedpur commissioning execution risk | An MoU has been signed for the Jamshedpur hospital with a targeted commissioning by end-FY27, adding a new greenfield ramp-up risk on top of the ongoing Raipur ramp-up. If both Raipur and Jamshedpur are in early-stage ramp-up simultaneously, network-level margins and ROCE could face compounded pressure. |